45 results about "Fibrin Seal" patented technology

An external mixer assembly is provided which externally mixes and delivers a first and a second component of a biological adhesive to tissues or organs for sealing wounds, stopping bleeding and the like. The first and second components are mixed immediately after exiting from separate outlet ports disposed in fluid communication with component reservoirs. In on embodiment, the external mixer assembly includes a housing having a housing head for enclosing therein a first reservoir containing the first component, and a second reservoir containing the second component. The housing further includes a discharge nozzle defining a longitudinal axis for enclosing therein a conduit assembly having a first and a second conduit in communication with the first and second reservoir, respectively. A deflector assembly is connected to the discharge nozzle. The deflector assembly includes a deflector plate to provide a space for initial mixing of the first and second components. The deflector plate is oriented in generally parallel juxtaposed relation distal to the distal face of the discharge nozzle. The first and second components are preferably fibrinogen and thrombin which intermix to form a fibrin sealant.

Methods and compositions are provided for preparing protein concentrates from protein comprising aqueous compositions. In the subject methods, an initial protein comprising aqueous compositions, such as whole blood or a derivative thereof, is contacted with a non-protein denaturant hydrogel under conditions sufficient for a substantial amount of water present in the composition to be absorbed by the hydrogel, resulting in the production of a protein concentrate, such as a fibrinogen rich composition. Of particularl interest is the use of the subject methods to prepare fibrinogen rich compositions, where such compositions produced according to the subject invention are useful in fibrin sealants, drug delivery vehicles and in a number of other diverse applications.

This invention provides a fibrin sealant bandage, wherein said fibrin sealant may be supplemented with at least one composition selected from, for example, one or more regulatory compounds, antibody, antimicrobial compositions, analgesics, anticoagulants, antiproliferatives, anti-inflammatory compounds, cytokines, cytotoxins, drugs, growth factors, interferons, hormones, lipids, demineralized bone or bone morphogenetic proteins, cartilage inducing factors, oligonucleotides polymers, polysaccharides, polypeptides, protease inhibitors, vasoconstrictors or vasodilators, vitamins, minerals, stabilizers and the like. Also disclosed are methods of preparing and / or using the unsupplemented or supplemented fibrin sealant bandage.

This invention provides a fibrin sealant dressing, wherein said fibrin sealant may be supplemented with at least one composition selected from, for example, one or more regulatory compounds, antibody, antimicrobial compositions, analgesics, anticoagulants, antiproliferatives, antiinflammatory compounds, cytokines, cytotoxins, drugs, growth factors, interferons, hormones, lipids, demineralized bone or bone morphogenetic proteins, cartilage inducing factors, oligonucleotides polymers, polysaccharides, polypeptides, protease inhibitors, vasoconstrictors or vasodilators, vitamins, minerals, stabilizers and the like. Also disclosed are methods of preparing and / or using the unsupplemented or supplemented fibrin sealant dressing.

Present invention depicts a poly-porous (micropore) hollow screws as diffusion chamber filled with core matrix for targeted delivery of growth factors and bone marrow stem cells. The screws comprise at least two parts: the distal part of the screw consists of the tip of the screw made of poly porous material and hollow inside proximally. It has threaded navel attached to the threaded nipple of the distal part of the proximal screw which has the screw head and is made of the solid material of the same kind. The screw head had hexagonal recess targeted for screw driver insertion. Assembly of screw created a chamber in the middle of the screw. The chamber is filled with core matrix consisting of gelatin nano-particles pre-impregnated with BMPs (BMP2 / BMP7 for bone or BMP12 for tendon, ligament) and fibrin sealants or Chitosan dispersed with bone marrow stem cells and / or other growth factors. Bioactive protein core material is prepared during the surgery and filled the chamber of the screw by the surgeon. Fibrin sealants or Chitosan will polymerize to form a gel to hold the growth factors and stem cell in place. The screw can be used as the lag screw or other function to provide mechanical fixation in variety of condition. Once the screw implanted in the human body, the fibrin sealant or Chitosin / gelatin nano-particles are gradually degraded and slowly release growth factors and stem cells via micropores of screw to facilitate the bone healing and regeneration. The gelatin nanoparticles and fibril sealant / or Chitosan matrix also serve as the scaffold and platform for bone in-growth to the screw or alternatively, the stem cell inside of screw can regenerate new bone, providing the biological fixation. At the mean time as the bone regenerate and / or in growth, mechanical strength of the screw increased.

Apparatus for delivering biologic sealant device that includes a pressure monitor coupled to the delivery device to measure pressure within the device. A method of treating a disc using the device as well as a kit including the device is described.

Techniques for treating visceral or parietal membrane and tissue defects include the application of a collagen biomatrix to the defect to repair and regenerate a visceral or parietal membrane, for example in patients suffering tissue defects or undergoing visceral or parietal surgical treatment. Such approaches avoid persistent tissue leaks and their consequences such as fluid leaks and air leaks. The use of collagen biomatrix, optionally in conjunction with a fibrin sealant, an anti-adhesive, or both, can minimize tissue leaks or fluid leaks in injured patients suffering tissue defects or subjects undergoing surgery such as visceral or parietal resections and other operations.

ClotFoam is a surgical sealant and hemostatic agent designed to be used in cases of non-compressible hemorrhage. It can be applied in the operating room through laparoscopic ports, or directly over lacerated tissue in laparotomy procedures or outside the operating room through a mixing needle and / or a spray injection method following abdominal, chest, extremities or other intracavitary severe trauma to promote hemostasis. Its crosslinking technology generates an adhesive three-dimensional polymeric network or scaffold that carries a fibrin sealant required for hemostasis. When mixed, Clotfoam produces a foam that spreads throughout a body cavity reaching the lacerated tissue to seal tissue and promote the coagulation cascade.The viscoelastic attachment properties of the foam as well as the rapid formation of a fibrin clot that ensure that the sealant remains at the site of application without being washed away by blood or displaced by movement of the target tissue .

Surgical methods of and kits for applying and stabilizing a mass of fibrin sealant or platelet concentrate at the site of surgical attachment of an implantable medical device to effect hemostasis to stem internal bleeding at the site of surgical attachment are disclosed. A mass of fibrin sealant or platelet concentrate is applied onto a porous fabric, whereby the mass is supported in the interstices or pores of the fabric, and the supported mass is applied against the site of high pressure blood leakage. The supported mass achieves hemostasis as it does not wash away from the site. The present invention is particularly useful to effect hemostasis at sutures and suture holes extending through thin-walled tissue valves and grafts when such tissue valves or grafts are sutured in place, particularly at high blood pressure sites as at the valve annulus of the aortic valve or the aorta.

The present invention relates to novel formulations comprising a dry powder fibrin sealant comprised a mixture of fibrinogen and / or thrombin, for use in the treatment of wounds or injuries, in particular for use as a topical hemostatic composition or for surgical intervention.

A hemostatic agent designed for use in cases of non-compressible hemorrhage. It can be applied through a mixing needle and / or a spray injection method following abdominal, chest, extremities or other intracavitary severe trauma to promote hemostasis, or it can be used for laparoscopic procedures or other surgical procedures in which compression is not possible or recommended. Its crosslinking technology generates an adhesive three-dimensional polymeric network or scaffold that carries a fibrin sealant required for hemostasis. When mixed, it produces a foam that spreads throughout a body cavity reaching the lacerated tissue to seal tissue and promote the coagulation cascade. The fibrin components are produced by a novel dialysis method which does not present thrombin to the immune system and can be maintained in solution for six weeks without significant proteolytic degradation.

ClotFoam is an hemostatic agent designed for non-compressible hemorrhage. It can be applied outside the operating room through a mixing needle and / or a spray injection method following abdominal, chest, extremities or other intracavitary severe trauma to promote hemostasis, or it can be used in the operating room for laparoscopic procedures or other surgical procedures in which compression is not possible or recommended. Its crosslinking technology generates an adhesive three-dimensional polymeric network or scaffold that carries a fibrin sealant required for hemostasis. When mixed, Clotfoam produces a foam that spreads throughout a body cavity reaching the lacerated tissue to seal tissue and promote the coagulation cascade. The viscoelastic attachment properties of the foam as well as the rapid formation of a fibrin clot that ensure that the sealant remains at the site of application without being washed away by blood or displaced by movement of the target tissue .

Present invention depicts a poly-porous (micropore) hollow screws as diffusion chamber filled with core matrix for targeted delivery of growth factors and bone marrow stem cells. The screws comprise at least two parts: the distal part of the screw consists of the tip of the screw made of poly porous material and hollow inside proximally. It has threaded navel attached to the threaded nipple of the distal part of the proximal screw which has the screw head and is made of the solid material of the same kind. The screw head had hexagonal recess targeted for screw driver insertion. Assembly of screw created a chamber in the middle of the screw. The chamber is filled with core matrix consisting of gelatin nano-particles pre-impregnated with BMPs (BMP2 / BMP7 for bone or BMP12 for tendon, ligament) and fibrin sealants or Chitosan dispersed with bone marrow stem cells and / or other growth factors. Bioactive protein core material is prepared during the surgery and filled the chamber of the screw by the surgeon. Fibrin sealants or Chitosan will polymerize to form a gel to hold the growth factors and stem cell in place. The screw can be used as the lag screw or other function to provide mechanical fixation in variety of condition. Once the screw implanted in the human body, the fibrin sealant or Chitosin / gelatin nano-particles are gradually degraded and slowly release growth factors and stem cells via micropores of screw to facilitate the bone healing and regeneration. The gelatin nanoparticles and fibril sealant / or Chitosan matrix also serve as the scaffold and platform for bone in-growth to the screw or alternatively, the stem cell inside of screw can regenerate new bone, providing the biological fixation. At the mean time as the bone regenerate and / or in growth, mechanical strength of the screw increased.

The present invention relates to a dry powder fibrin sealant which comprises a mixture of fibrinogen and thrombin for use in surgery, trauma and other wounds or injuries. It further relates to novel formulations comprising said dry powder fibrin sealant for use in the treatment of wounds or for surgical intervention or as a topical hemostat.

A site-specific antibiotic delivery system and related method comprising a fibrin sealant and an antibiotic releasably bound to the fibrin sealant, wherein the antibiotic is delivered in situ and wherein the dose of antibiotic delivered to the organism is sufficient to kill substantially all antibiotic-resistant bacteria present in an infectious focus.

The present invention relates to a tissue sealant in which collagen and fibrin are mixed and to a method for preparing same. To this end, the method of the present invention comprises the steps of: mixing a first material using fibrinogen and aprotinin; mixing a second material using thrombin, calcium chloride, and collagen; and preparing a third material by mixing the first material and the second material. The tissue sealant prepared by the method may supplement weaknesses, i.e. strength and degradability, of the fibrin sealant which is currently available in the commercial marketplace. Further, the tissue sealant of the present invention is cytophilic and activates blood platelets contained in blood so as to induce tissue regeneration. Thus, quality and reliability of products can be significantly improved so as to satisfy various needs of consumers who are users, thereby presenting good image.

A fibrin-based hemostatic agent suitable for both civilian and military use is disclosed. The hemostatic agent comprises (i) nanoparticles to which a plurality of Knob-A recognition sequences are attached, and (ii) coiled-coils of recombinantly-produced human fibrinogen α and chains and the γ chain globular domain. A delivery system for the hemostatic agent also is disclosed, which additionally comprises means for delivering (i) and (ii) to a wound site. The delivery means may be a CO2 canister or a shaker jet.

ClotFoam is an hemostatic agent designed for use in cases of non-compressible hemorrhage. It can be applied outside the operating room through a mixing needle and / or a spray injection method following abdominal, chest, extremities or other intracavitary severe trauma to promote hemostasis, or it can be used in the operating room for laparoscopic procedures or other surgical procedures in which compression is not possible or recommended. Its crosslinking technology generates an adhesive three-dimensional polymeric network or scaffold that carries a fibrin sealant required for hemostasis. When mixed, Clotfoam produces a foam that spreads throughout a body cavity reaching the lacerated tissue to seal tissue and promote the coagulation cascade. The viscoelastic attachment properties of the foam as well as the rapid formation of a fibrin clot that ensure that the sealant remains at the site of application without being washed away by blood or displaced by movement of the target tissue. The fibrin components are produced by a novel method which does not present thrombin to immune system and can be maintained in solution for six weeks without significant proteolytic degradation.

Apparatus for delivering biologic sealant device that includes a pressure monitor coupled to the delivery device to measure pressure within the device. A method of treating a disc using the device as well as a kit including the device is described.

The present invention relates to a fibrin matrix, its preparation and use for effectively sealing a defect in a mucosa or other moist tissue.

The present invention relates to a fibrin sealant kit comprising purified fibrinogen and thrombin. The invention particularly relates to an improved chromatographic process for the purification of thrombin and fibrinogen components devoid of any significant plasminogen and other impurities. The absence of plasminogen facilitates the exclusion of a proteolytic inhibitor (aprotinin) from among the kit components.

The present invention relates to a fibrin matrix, its preparation and use for effectively sealing a defect in a mucosa or other moist tissue.

A method for modifying the properties of a fibrin matrix relative to growth and ingrowth of cells, wherein for forming the fibrin matrix a fibrinogen is used consisting of a selected fibrinogen variant or a fibrinogen enriched or depleted in a selected fibrinogen variant. In particular, the use of high-molecular weight (HMW) fibrinogen leads to a fibrin having accelerated angiogenesis properties, while the use of low-molecular weight (LMW and / or LMW′) fibrinogen leads to fibrin having decelerated angiogenesis properties. The use of HMW fibrinogen when setting up angiogenesis tests results in that the tests require less time. Fibrin sealants on the basis of HMW fibrinogen can be used for burns, to promote wound healing or to inhibit scar tissue. Fibrin sealants on the basis of LMW or LMW′ fibrinogen are useful to inhibit adhesions and tumor growth, for instance after surgical operations.